How is psoriatic arthritis diagnosed?

How to Diagnose Psoriatic Arthritis

Psoriatic arthritis should be diagnosed using the CASPAR criteria, which require established inflammatory arthritis (tender/swollen joints with prolonged morning stiffness) plus at least 3 points from specific clinical features, achieving 98.7% specificity and 91.4% sensitivity. 1

Clinical Diagnostic Framework

CASPAR Criteria Application

The diagnosis requires established inflammatory articular disease (defined as tender and swollen joints with prolonged morning or immobility-induced stiffness) PLUS at least 3 points from the following features: 1, 2

• Current psoriasis = 2 points
• Personal history of psoriasis (unless current psoriasis present) = 1 point
• Family history of psoriasis (unless current or personal history present) = 1 point
• Current dactylitis or documented history by rheumatologist = 1 point
• Juxta-articular new bone formation on radiographs = 1 point
• Rheumatoid factor negativity = 1 point
• Typical psoriatic nail dystrophy (onycholysis, pitting, hyperkeratosis) = 1 point

Essential Physical Examination Findings

Perform a comprehensive 68 tender/66 swollen joint count that specifically includes distal interphalangeal (DIP) joints of hands and proximal/distal interphalangeal joints of feet, as DIP involvement is characteristic of PsA and uncommon in rheumatoid arthritis. 2

Look for dactylitis ("sausage digit"), which represents a combination of enthesitis of tendons/ligaments plus synovitis involving an entire digit—this is common in PsA but rare in rheumatoid arthritis. 1

Examine for enthesitis at common sites: plantar fascia insertion, Achilles tendon insertion, and ligamentous attachments to ribs, spine, and pelvis. 1

Assess skin and nails thoroughly for psoriatic plaques, nail pitting, onycholysis, and hyperkeratosis, as nail disease is especially common in patients with DIP joint involvement. 1

Document the pattern of joint involvement: PsA typically shows asymmetric distribution, involves DIP joints, and presents with joints that are less tender/swollen compared to rheumatoid arthritis. 1

Laboratory Evaluation

No single serologic test definitively diagnoses PsA—the diagnosis remains clinical. 1, 3

Check rheumatoid factor (RF), which should be negative in most cases; however, 5-13% of PsA patients may be RF-positive, so a positive RF does not exclude PsA if other features are present. 1, 3

Measure acute-phase reactants (ESR/CRP), recognizing that they are elevated in only approximately 50% of patients; an elevated ESR is associated with higher risk of radiographic damage progression. 2, 3

Imaging Studies

Plain Radiography

Obtain radiographs to identify characteristic features: a combination of destructive changes (erosions, tuft resorption, osteolysis) and bone proliferative features (periostitis, ankylosis, spur formation, non-marginal syndesmophytes). 1, 3

Use radiographs to demonstrate extent and anatomical distribution of joint involvement and to assess for asymptomatic spine or sacroiliac involvement when axial disease is suspected. 1, 3

Ultrasound (Power Doppler)

Ultrasound is superior to clinical examination alone for detecting both inflammation and structural damage in PsA. 3

Use ultrasound to identify synovial hypertrophy, hyperemia, erosions, and enthesitis; the presence of erosions, synovial hypertrophy, and hyperemia raises the post-test probability of inflammatory arthritis to 50-94%. 3

Recognize that isolated mild synovial hypertrophy is nonspecific and has limited diagnostic relevance. 3

Magnetic Resonance Imaging

MRI with intravenous gadolinium is more sensitive than ultrasound, particularly for early disease, and can detect bone-marrow edema and synovitis that predict disease progression. 3

Current data are inconclusive regarding overall superiority of MRI versus ultrasound, so choice should be based on availability and clinical context. 3

Baseline Assessment Measures

At diagnosis, document the following domains as recommended by the OMERACT 8 conference consensus: 2

• Peripheral joint assessment (68 tender/66 swollen joints)
• Patient-reported pain on visual analogue or category rating scale
• Patient global assessment of disease activity
• Physical function using Health Assessment Questionnaire (HAQ)
• Health-related quality of life (SF-36 or PsAQoL)
• Fatigue assessment (patient self-report or FACIT)
• Acute phase reactants (CRP or ESR)

Radiographic assessment should be performed according to clinical manifestation and physician judgment. 2

Differential Diagnosis Considerations

Distinguishing from Rheumatoid Arthritis

PsA differs from RA by showing less symmetric joint distribution, DIP involvement, presence of dactylitis and enthesitis, absence of rheumatoid nodules and high-titer RF, and characteristic skin/nail findings. 2, 1

Female patients with PsA may present with symmetric polyarticular inflammatory arthritis resembling RA in 20% of cases, making skin and nail findings critical for differentiation. 1

Distinguishing from Osteoarthritis

PsA features inflammatory joint swelling rather than osteophyte-driven Heberden's nodes; inflammatory swelling improves with activity whereas OA pain worsens with activity. 3

Recognizing PsA Sine Psoriasis

In approximately 20% of patients, rheumatological manifestations precede cutaneous lesions; these patients can be diagnosed with PsA sine psoriasis if there is a family history of psoriasis, dactylitis, DIP arthritis, or HLA-Cw6 positivity. 4

Multidisciplinary Confirmation

Diagnosis should ideally be confirmed jointly: psoriasis verified by a dermatologist and inflammatory musculoskeletal disease confirmed by a rheumatologist, or either confirmed by an appropriately qualified health professional. 2, 5

Dermatologists should actively screen for PsA at each visit in patients with psoriasis, as 84% of PsA patients had cutaneous manifestations for an average of 12 years before arthritis onset. 1

Refer to rheumatology if uncomfortable with evaluation or treatment, as early diagnosis and treatment are critical to prevent persistent inflammation, progressive joint damage, severe physical limitations, and disability. 1

Common Pitfalls to Avoid

Do not rely solely on correlation between skin and joint severity, as the severity of skin disease and arthritis usually do not correlate with each other. 1

Do not exclude PsA based on negative RF alone, as PsA is a seronegative spondyloarthropathy and some patients may have coincidental RF positivity. 1

Do not overlook nail examination, as nail disease is commonly found in PsA patients, especially those with DIP joint involvement. 1

Ask specifically about prolonged morning stiffness lasting >30 minutes, as this is a valuable screening question for all patients with psoriasis at each visit. 6